{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001774","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.510929+00:00","generated_at":"2026-05-16T10:52:02.021711+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"medium","headline":"Acumen updates corporate presentation with new EBD data, ACU234 pipeline addition","bullets":["Nonclinical murine brain exposure data for Enhanced Brain Delivery program presented at CTAD 2025 included.","Updated fluid biomarker data from Phase 1 INTERCEPT-AD study added to presentation.","ACU234, a new candidate under the EBD program, now listed in pipeline.","Presentation posted on company website for use in conferences and communications."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001774","json":"https://secwatch.observer/filing/0001628280-26-001774.json","markdown":"https://secwatch.observer/filing/0001628280-26-001774.md","text":"https://secwatch.observer/filing/0001628280-26-001774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/0001628280-26-001774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/abos-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:02.021711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}